Augmentin DILI Use Case [proposed by Exposures Provider]

[karafecho]

Prior to the breast cancer use case, we had considered a DILI use case. At the time, Multi-omics EHR Provider and Clinical Data Provider were capable of answering questions related to DILI, but Exposures Provider was only semi-capable, as we had not yet stood-up our planned ICEES+ DILI instance. We were going to move forward regardless until we realized that a breast cancer use case was something that all of the clinical KPs (including Connections Hypothesis Provider) could contribute to.

However, Exposures Provider received an Augmentin DILI dataset from the international DILIN network just this past Tuesday, 3/16/2021. We should be able to expose the data via ICEES+ fairly quickly. As such, I'm inclined to rethink this use case.

Thoughts from others?

[karafecho]

As noted above, this use case should work for Multi-omics EHR Provider, Clinical Data Provider, Exposures Provider, and Connections Hypotheses Provider, albeit with caveats. By way of Genetics Provider, I think we can then link to Genes and from there to ChemicalSubstances or Drugs, with an overall goal of identifying candidate drug targets or drugs for repurposing.

[karafecho]

Also see #4.

[karafecho]

See this folder for details regarding a TRAPI query plan.

[karafecho]

Closing, largely complete and will be included in Dec demo as kick-off slide to live portion of demo.